JP2020200352A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020200352A5 JP2020200352A5 JP2020161995A JP2020161995A JP2020200352A5 JP 2020200352 A5 JP2020200352 A5 JP 2020200352A5 JP 2020161995 A JP2020161995 A JP 2020161995A JP 2020161995 A JP2020161995 A JP 2020161995A JP 2020200352 A5 JP2020200352 A5 JP 2020200352A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- subject
- use according
- apoe4
- mmse
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 12
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 206010001897 Alzheimer's disease Diseases 0.000 claims 2
- SNKZJIOFVMKAOJ-UHFFFAOYSA-N Homotaurine Chemical compound NCCCS(O)(=O)=O SNKZJIOFVMKAOJ-UHFFFAOYSA-N 0.000 claims 2
- 229960003570 tramiprosate Drugs 0.000 claims 2
- 206010057668 Cognitive disease Diseases 0.000 claims 1
- 229940100691 Oral Capsule Drugs 0.000 claims 1
- 229940096978 Oral Tablet Drugs 0.000 claims 1
- 239000007935 oral tablet Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
Claims (10)
- （ｉ）ＡＰＯＥ４／４ホモ接合であり；かつ（ｉｉ）組成物の初回投与の前の６０日以内に行われたミニメンタルステート検査（ＭＭＳＥ）で≧２２のベースラインＭＭＳＥスコアを有する；あるいは
（ｉｉ）ＡＰＯＥ４ヘテロ接合であり；かつ（ｉｉ）組成物の初回投与の前の６０日以内に行われたミニメンタルステート検査（ＭＭＳＥ）で≧１６のベースラインＭＭＳＥスコアを有する
と決定される対象のみにおけるアルツハイマー病の処置における使用のための、バリル−３−アミノ−１−プロパンスルホン酸またはこれらの薬学的に許容可能な塩を含む医薬組成物。 - 前記対象がＡＰＯＥ４／４ホモ接合であり、かつ、２２〜２６のベースラインＭＭＳＥスコアを有する、請求項１に記載の使用のための組成物。
- 前記対象がＡＰＯＥ４ヘテロ接合であり、かつ、１６〜１９のベースラインＭＭＳＥスコアを有する、請求項１に記載の使用のための組成物。
- 前記医薬組成物の各投与後に、前記医薬組成物が、１００ｍｇ〜１５０ｍｇのトラミプロセートに等しいトラミプロセート曝露量を達成する、請求項１〜３のいずれか一項に記載の使用のための組成物。
- 前記医薬組成物が、２６０と２７０ｍｇの間のバリル−３−アミノ−１−プロパンスルホン酸を含む、請求項４に記載の使用のための組成物。
- 前記組成物が、２６５ｍｇのバリル−３−アミノ−１−プロパンスルホン酸を含み、前記組成物が、即時放出の経口錠剤またはカプセルとして製剤化される、請求項５に記載の使用のための組成物。
- 前記医薬組成物が１日に２回投与される、請求項１〜６のいずれか一項に記載の使用のための組成物。
- 前記対象が８５歳以下である、請求項１〜７のいずれか一項に記載の使用のための組成物。
- 前記処置が前記対象の認知低下を減少させる、請求項１〜８のいずれか一項に記載の使用のための組成物。
- 対象のＡＰＯＥ４ステータスと該対象のアルツハイマー病の重篤度を、バリル−３−アミノ−１−プロパンスルホン酸による処置に関する対象の適合性の指標とする方法であって、
該対象がＡＰＯＥ４／４ホモ接合であり、かつ≧２２のベースラインミニメンタルステート検査（ＭＭＳＥ）スコアを有する；あるいは
該対象がＡＰＯＥ４ヘテロ接合であり、かつ≧１６のベースラインミニメンタルステート検査（ＭＭＳＥ）スコアを有する
場合に、該対象が処置に適合していることが示されることを特徴とする、方法。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022128786A JP2022145949A (ja) | 2015-09-10 | 2022-08-12 | 特定の患者集団において神経変性障害を処置する方法 |
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562216404P | 2015-09-10 | 2015-09-10 | |
| US62/216,404 | 2015-09-10 | ||
| US201662290287P | 2016-02-02 | 2016-02-02 | |
| US62/290,287 | 2016-02-02 | ||
| US201662302027P | 2016-03-01 | 2016-03-01 | |
| US62/302,027 | 2016-03-01 | ||
| US201662365809P | 2016-07-22 | 2016-07-22 | |
| US62/365,809 | 2016-07-22 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018512564A Division JP6789579B2 (ja) | 2015-09-10 | 2016-09-09 | 特定の患者集団において神経変性障害を処置する方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022128786A Division JP2022145949A (ja) | 2015-09-10 | 2022-08-12 | 特定の患者集団において神経変性障害を処置する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020200352A JP2020200352A (ja) | 2020-12-17 |
| JP2020200352A5 true JP2020200352A5 (ja) | 2021-04-30 |
| JP7128536B2 JP7128536B2 (ja) | 2022-08-31 |
Family
ID=58240195
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018512564A Active JP6789579B2 (ja) | 2015-09-10 | 2016-09-09 | 特定の患者集団において神経変性障害を処置する方法 |
| JP2020161995A Active JP7128536B2 (ja) | 2015-09-10 | 2020-09-28 | 特定の患者集団において神経変性障害を処置する方法 |
| JP2022128786A Pending JP2022145949A (ja) | 2015-09-10 | 2022-08-12 | 特定の患者集団において神経変性障害を処置する方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018512564A Active JP6789579B2 (ja) | 2015-09-10 | 2016-09-09 | 特定の患者集団において神経変性障害を処置する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022128786A Pending JP2022145949A (ja) | 2015-09-10 | 2022-08-12 | 特定の患者集団において神経変性障害を処置する方法 |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US11191742B2 (ja) |
| EP (2) | EP3347002B1 (ja) |
| JP (3) | JP6789579B2 (ja) |
| KR (2) | KR102412997B1 (ja) |
| CN (3) | CN108289870A (ja) |
| AU (1) | AU2016319107B2 (ja) |
| CA (1) | CA2997376C (ja) |
| DK (1) | DK3347002T3 (ja) |
| ES (1) | ES2952727T3 (ja) |
| FI (1) | FI3347002T3 (ja) |
| HK (1) | HK1257874A1 (ja) |
| HR (1) | HRP20230809T1 (ja) |
| HU (1) | HUE062511T2 (ja) |
| LT (1) | LT3347002T (ja) |
| MD (1) | MD3347002T2 (ja) |
| MX (2) | MX2018003023A (ja) |
| PL (1) | PL3347002T3 (ja) |
| PT (1) | PT3347002T (ja) |
| RS (1) | RS64481B1 (ja) |
| SI (1) | SI3347002T1 (ja) |
| WO (1) | WO2017044840A1 (ja) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2960625T3 (es) | 2014-03-21 | 2024-03-05 | Alzheon Inc | Compuestos para uso en el tratamiento de la enfermedad de Alzheimer en pacientes de ApoE4+/+ |
| US11191742B2 (en) * | 2015-09-10 | 2021-12-07 | Alzheon, Inc. | Methods of treating neurodegenerative disorders in a particular population |
| CN108623501B (zh) | 2017-03-21 | 2022-04-19 | 润佳（苏州）医药科技有限公司 | 同位素富集的3-氨基-1-丙磺酸衍生物及其用途 |
| CN110003058B (zh) | 2018-01-04 | 2022-01-25 | 润佳（苏州）医药科技有限公司 | 3-((l-缬氨酰基)氨基)-3,3-二氘-1-丙磺酸晶型、制备方法及用途 |
| SG11202100767XA (en) * | 2018-08-01 | 2021-02-25 | Alzheon Inc | Methods for treating neurodegenerative disorders |
| HRP20231576T1 (hr) * | 2018-08-01 | 2024-03-15 | Alzheon, Inc. | Derivati sulfopropanske kiseline za liječenje neurodegenerativnih poremećaja |
| CN111170901A (zh) * | 2018-11-13 | 2020-05-19 | 润佳（苏州）医药科技有限公司 | 3-((l-缬氨酰基)氨基)-1-丙磺酸晶型、制备方法及其用途 |
| KR20220024434A (ko) | 2019-06-17 | 2022-03-03 | 알제온, 인크. | 신경퇴행성 장애를 치료하는 방법 |
| WO2023107658A1 (en) * | 2021-12-09 | 2023-06-15 | Alzheon, Inc. | Alz-801 for use in treating alzheimer's disease |
| WO2023150381A1 (en) * | 2022-02-07 | 2023-08-10 | Alzheon, Inc. | Alz-801 for use in treating a covid-19 associated neurological symptom |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5698155A (en) | 1991-05-31 | 1997-12-16 | Gs Technologies, Inc. | Method for the manufacture of pharmaceutical cellulose capsules |
| NZ257215A (en) | 1992-10-13 | 1996-12-20 | Univ Duke | Diagnosis or prognosis of alzheimers using the presence of apolipoprotein e type 4 as an indicator and apolipoprotein e isoform specific antibodies |
| US20050031651A1 (en) | 2002-12-24 | 2005-02-10 | Francine Gervais | Therapeutic formulations for the treatment of beta-amyloid related diseases |
| US20070010573A1 (en) | 2003-06-23 | 2007-01-11 | Xianqi Kong | Methods and compositions for treating amyloid-related diseases |
| US20050142191A1 (en) | 2003-06-23 | 2005-06-30 | Neurochem (International) Limited | Pharmaceutical formulations of amyloid inhibiting compounds |
| US20060079578A1 (en) | 2003-06-23 | 2006-04-13 | Julie Laurin | Pharmaceutical formulations of amyloid inhibiting compounds |
| SG145784A1 (en) | 2003-08-11 | 2008-09-29 | California Inst Of Techn | Microfluidic large scale integration |
| KR20070120190A (ko) * | 2005-04-12 | 2007-12-21 | 뉴로켐 (인터내셔널) 리미티드 | 아밀로이드 억제 화합물의 제약 제제 |
| DK3851447T3 (da) | 2006-10-12 | 2023-12-04 | Bellus Health Inc | Fremgangsmåder, forbindelser, sammensætninger og vehikler til administration af 3-amino-1-propansulfonsyre |
| ES2587014T3 (es) | 2006-11-24 | 2016-10-20 | Ac Immune S.A. | Derivados de N-(metil)-piridin-2-amina para el tratamiento de enfermedades asociadas a proteínas amiloides o de tipo amiloide |
| JO3076B1 (ar) | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
| US20120009125A1 (en) | 2010-07-06 | 2012-01-12 | Lombard Jay L | Apoe4 and apoj biomarker-based prevention and treatment of dementia |
| ES2705027T3 (es) | 2010-08-19 | 2019-03-21 | Buck Institute For Age Res | Métodos de tratamiento del deterioro cognitivo leve (DCL) y trastornos relacionados |
| PT2994160T (pt) * | 2013-05-06 | 2019-08-07 | Baxalta Inc | Tratamento de sub-populações com doença de alzheimer com imunoglobulina g combinada |
| TWI705824B (zh) | 2014-02-08 | 2020-10-01 | 美商建南德克公司 | 治療阿茲海默症之方法 |
| ES2960625T3 (es) * | 2014-03-21 | 2024-03-05 | Alzheon Inc | Compuestos para uso en el tratamiento de la enfermedad de Alzheimer en pacientes de ApoE4+/+ |
| US11191742B2 (en) * | 2015-09-10 | 2021-12-07 | Alzheon, Inc. | Methods of treating neurodegenerative disorders in a particular population |
-
2016
- 2016-09-09 US US15/758,405 patent/US11191742B2/en active Active
- 2016-09-09 JP JP2018512564A patent/JP6789579B2/ja active Active
- 2016-09-09 SI SI201631729T patent/SI3347002T1/sl unknown
- 2016-09-09 FI FIEP16845181.3T patent/FI3347002T3/fi active
- 2016-09-09 AU AU2016319107A patent/AU2016319107B2/en active Active
- 2016-09-09 PT PT168451813T patent/PT3347002T/pt unknown
- 2016-09-09 DK DK16845181.3T patent/DK3347002T3/da active
- 2016-09-09 CN CN201680052760.4A patent/CN108289870A/zh active Pending
- 2016-09-09 CN CN202310582394.5A patent/CN116712423A/zh active Pending
- 2016-09-09 HR HRP20230809TT patent/HRP20230809T1/hr unknown
- 2016-09-09 KR KR1020187009381A patent/KR102412997B1/ko active IP Right Grant
- 2016-09-09 ES ES16845181T patent/ES2952727T3/es active Active
- 2016-09-09 EP EP16845181.3A patent/EP3347002B1/en active Active
- 2016-09-09 CA CA2997376A patent/CA2997376C/en active Active
- 2016-09-09 PL PL16845181.3T patent/PL3347002T3/pl unknown
- 2016-09-09 CN CN202310582365.9A patent/CN116712422A/zh active Pending
- 2016-09-09 KR KR1020227009418A patent/KR102547164B1/ko active IP Right Grant
- 2016-09-09 MD MDE20180700T patent/MD3347002T2/ro unknown
- 2016-09-09 LT LTEPPCT/US2016/051091T patent/LT3347002T/lt unknown
- 2016-09-09 MX MX2018003023A patent/MX2018003023A/es unknown
- 2016-09-09 WO PCT/US2016/051091 patent/WO2017044840A1/en active Application Filing
- 2016-09-09 HU HUE16845181A patent/HUE062511T2/hu unknown
- 2016-09-09 RS RS20230603A patent/RS64481B1/sr unknown
- 2016-09-09 EP EP23176559.5A patent/EP4275750A3/en active Pending
-
2018
- 2018-03-09 MX MX2022003128A patent/MX2022003128A/es unknown
-
2019
- 2019-01-07 HK HK19100235.4A patent/HK1257874A1/zh unknown
-
2020
- 2020-09-28 JP JP2020161995A patent/JP7128536B2/ja active Active
-
2021
- 2021-09-17 US US17/477,886 patent/US20220096406A1/en not_active Abandoned
-
2022
- 2022-08-12 JP JP2022128786A patent/JP2022145949A/ja active Pending
-
2023
- 2023-09-06 US US18/462,238 patent/US20230414541A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020200352A5 (ja) | ||
| AU2017312660B2 (en) | Methods of treating eosinophilic esophagitis | |
| Healy et al. | An association between recurrent oro‐genital ulceration and non‐steroidal anti‐inflammatory drugs | |
| Marks et al. | A new form of long QT syndrome associated with syndactyly | |
| JP2018526407A5 (ja) | ||
| JP2012510987A (ja) | ザレプロン胃内滞留性薬剤送達システム | |
| FI3347002T3 (fi) | Alzheimerin taudin hoitaminen tietyssä potilaspopulaatiossa | |
| JP2022123032A (ja) | エダラボン医薬組成物 | |
| US20100035927A1 (en) | Medicament for prophylactic and/or therapeutic treatment of alzheimer-type dementia | |
| BR112020008128A2 (pt) | comprimidos de liberação retardada de deferiprona e métodos para utilização dos mesmos | |
| JP2017508737A5 (ja) | ||
| JP2009242365A (ja) | 経口医薬組成物 | |
| JP2015521647A5 (ja) | ||
| Smith et al. | Lesch-Nyhan syndrome: a case report | |
| JP2006528949A5 (ja) | ||
| Hunchaisri et al. | Effectiveness of oral zinc supplementation in the treatment of idiopathic sudden sensorineural hearing loss (ISSNHL) | |
| RU2237475C1 (ru) | Комбинированный препарат для устранения симптомов простудных заболеваний и гриппа (варианты) | |
| JP2012031141A (ja) | 骨髄異形性症候群を治療するための組成物および方法 | |
| JP2004002362A (ja) | くしゃみ抑制組成物 | |
| US20050227949A1 (en) | Compositions and methods for treatment of viral and bacterial infections | |
| EP3244885B1 (en) | Lipoic acid for treating or preventing threatened miscarriage or preterm delivery | |
| JP2012025734A (ja) | 骨髄異形性症候群を治療するための組成物および方法 | |
| EP2184284B1 (en) | Preventive, inhibitor or remedy for cerebral aneurysm comprising ibudilast as an active ingredient | |
| JP7291380B2 (ja) | 鼻水又は鼻づまりの口腔粘膜投与用即効性改善剤 | |
| JP2021506907A5 (ja) |